Molecular Partners Announces Scientific Leadership Transition After Successful Transformation of Research Organization to Focus on Novel DARPin® Therapeutics in Oncology

Molecular Partners Announces Scientific Leadership Transition After Successful Transformation of Research Organization to Focus on Novel DARPin® Therapeutics in Oncology

Pamela A. Trail, Ph.D., to transition from Chief Scientific Officer to strategic consultant;
Daniel Steiner, Ph.D., to assume leadership of research organization

Zurich-Schlieren, Switzerland, June 11, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that Pamela A. Trail, Ph.D., will depart from her role as Chief Scientific Officer effective July 1, 2019. The company’s Senior Vice President of Research Daniel Steiner, Ph.D., will assume leadership of the research department of the company. The transition completes the successful transformation of the company’s research organization around a defined set of therapeutic strategies in oncology. As part of the transition, Dr. Trail will continue to support the company as a strategic consultant.

“It has been a pleasure to be part of the transformation of Molecular Partners from a platform-based company to an oncology-focused company with a strong pipeline of DARPin® therapeutic candidates,” said Dr. Trail. “I look forward to supporting the Molecular Partners leadership team to bring these candidates to patients and also to assist in developing additional novel therapeutic designs.”

“I would like to thank Pamela for the outstanding contributions she made to define and focus our research activities and advance multiple promising new product candidates through the development pipeline,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners. “We will build upon that strong foundation as Daniel assumes leadership of our research team and we continue to progress our multiple promising early stage pipeline candidates with novel therapeutic DARPin® designs in the area of oncology.”

Dr. Trail was appointed CSO of Molecular Partners in June 2018. Under Dr. Trail’s leadership, the Molecular Partners research team has made rapid progress in the company’s oncology focus areas:

  • Tumor-local immunomodulators: Molecular Partners’ first product candidate MP0310, which was the subject of the company’s December 2018 partnership with Amgen, is positioned to move into Phase 1 in H2 2019; a second candidate, the FAPxCD-40 DARPin®, is approaching development status.
  • Peptide MHC DARPin®: Multiple candidates are progressing, both in-house and also within a dedicated research collaboration with Gilead.
  • T-cell engagers: The company’s anti-CD3-DARPin® has been successfully established and the first product candidates presented in April 2019 at the PEGS conference in Boston.
  • DARPin®-drug conjugates: The company continues to make progress in designing DARPin® drug conjugates for the treatment of solid tumors. Data were presented in April 2019 at the AACR conference in Atlanta, Georgia.

Financial Calendar

August 27, 2019 Publication of Half-year Results 2019 (unaudited)
October 31, 2019 Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than five targets, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in preclinical development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid and hematological tumors. MP0274, the second-most advanced DARPin® candidate owned by Molecular Partners, binds to Her2 and inhibits downstream signaling, which leads to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its “I/O toolbox” and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

INTERIM STATEMENT BY MANAGEMENT – Q1 2019: Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative oncology DARPin® candidates presented; Recruitment hold in MP0250 NSCLC trial; Ongoing focus on multiple myeloma for MP0250 clinical development

Research & Development:

  • MP0250 (VEGF x HGF) in MM: Additional patient data from ongoing Phase 2 study of MP0250 in combination with Velcade® (PI) support previously observed response rates and duration of treatment
  • MP0250 in combination with osimertinib in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC): Enrollment of new patients on hold due to adverse events; Strategic implications under review
  • MP0274 (Her2) progressing in dose-escalation study in Her2-positive cancer patients
  • Immuno-oncology: USD 50 million upfront payment collected in Q1 2019 from Amgen; MP0310 (FAP x 4-1BB) is on track to move into Phase 1 clinical trials in H2 2019
  • Molecular Partners continues to explore DARPin® molecules targeting peptide-MHC complexes in collaboration with Gilead
  • Preclinical data on FAP x CD40 multi-DARPin® molecule and on DARPin® drug conjugates (DDCs) presented at AACR 2019
  • Preclinical data for CD3 DARPin® platform presented at PEGS Boston in April 2019
  • Abicipar (VEGF): MAPLE trial with improved manufacturing process demonstrated decreased intraocular inflammation; abicipar is the first anti-VEGF therapy to maintain initial vision gains on a true fixed 12-week dosing interval; Allergan expects to file BLA to FDA for H1 2019

Team:

  • Talent base with 123 full-time employees (+9% year-on-year), reflecting ongoing build-out of research and clinical development expertise

Financial Highlights:

  • Strong financial position with CHF 136.5 million in cash and short-term deposits as of March 31, 2019
  • Net cash from operating activities of CHF 37.5 million in Q1 2019, mainly reflecting collection of USD 50 million Amgen receivable
  • FY 2019 expense guidance reduced to CHF 60-70 million mainly due to suspended enrollment into NSCLC trial and reduced investments in manufacturing scale-up for MP0250

 

Zurich-Schlieren, Switzerland, May 9, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending March 31, 2019.

“Our team is focused on delivering on our strategic priorities by advancing clinical candidates MP0250 and MP0274 and by bringing our first immuno-oncology compound MP0310 to patients with our partner Amgen,” said Dr. Patrick Amstutz, CEO of Molecular Partners. “Additionally, our pioneering early-stage pipeline — including a tumor-localized CD40 activator (FAP x CD40), pMHC-complex targeting with DARPin® molecules, DARPin® CD3 platform and DARPin® drug conjugates — promises to break new ground in their therapeutic space and to further augment our robust DARPin® platform.”

Oncology: Update of MP0250 in multiple myeloma

MP0250, Molecular Partners’ lead oncology asset, is a multi-DARPin® candidate that targets hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF), two prominent tumor escape pathways, and has the potential to reverse resistance to standard of care cancer therapies.

The phase 2 study for MP0250 in combination with proteasome inhibitors (PIs) is being conducted at centers in Germany, Poland and Italy and continues to progress well. This study is evaluating MP0250 in combination with bortezomib (Velcade®) and dexamethasone in patients with multiple myeloma who have failed standard therapies. Additional patient data from the ongoing phase 2 study of MP0250 in combination with Velcade® (PI) support previously observed response rates and duration of treatment.

Pending progress of the discussions with the FDA regarding the adverse events identified in the NSCLC study, the company is planning the initiation of a phase 2 study for MP0250 in combination with IMiDs in refractory multiple myeloma in the US with the goal to open recruitment in 2019.

Update of MP0250 in Non-Small Cell Lung Cancer (NSCLC)

Molecular Partners has suspended enrollment of new patients into the Phase 1b/2 clinical study of MP0250 in combination with osimertinib (Tagrisso®) in patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) following observation of adverse events in the kidney in this study leading to a partial clinical hold. Patient safety is of paramount importance to Molecular Partners. The company is working with the FDA to lift the hold by examining the relationship between the dose and duration of exposure to MP0250 and risk of renal injury. These side effects are not considered by investigators to be causally related to osimertinib. Strategic implications are under review.

MP0274 in HER2-positive solid tumors

MP0274 is a multi-DARPin® product candidate in Phase 1 trial for the treatment of HER2-positive solid tumors. Recruitment in the dose escalation phase continues. Further updates on the safety profile of MP0274 are expected in H2 2019.

Immuno-oncology: MP0310 on track to move into clinic in H2 2019

On December 19, 2018, the company announced a collaboration and license agreement with Amgen for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to Fibroblast Activating Protein (FAP) on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).

Under the terms of the agreement, Amgen obtains exclusive global development and commercial rights for MP0310. The parties will jointly evaluate MP0310 in combination with Amgen’s oncology pipeline products, including its investigational BiTE® (bispecific T cell engager) molecules. Under the agreement, Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin® pipeline products in combination with MP0310.

In January 2019, Molecular Partners collected an upfront payment of USD 50 million. The company is further eligible to receive up to USD 497 million in development, regulatory and commercial milestone payments, as well as double-digit, tiered royalties up to the high teens. The parties agreed to share the clinical development costs in defined percentages for the first three indications subject to certain conditions. For all additional clinical trials, Amgen is responsible for all development costs. Molecular Partners and Amgen continue to expect to enter into clinical phase 1 trials for MP0310 in H2 2019, in line with previously communicated plans.

Immuno-oncology: Molecular Partners and Gilead join forces in targeting peptide-MHC complexes

In March 2019, Molecular Partners and Gilead announced a collaboration exploring the potential of DARPin® molecules to selectively bind to peptide-MHC complexes. Peptide-MHC complexes provide entry to access the vast intracellular target space. However, to date, peptide-MHC complexes have been notoriously difficult to target with antibody-based therapeutics. Molecular Partners is evaluating whether DARPin® molecules provide a platform to selectively access this new therapeutic space in oncology.

Immuno-oncology: Preclinical data on FAP x CD40 multi-DARPin® molecule presented

Molecular Partners presented additional preclinical data on the company’s immuno-oncology platform at the 2019 annual meeting of the American Association for Cancer Research (AACR) in Atlanta. Using Molecular Partners’ modular immuno-oncology toolbox, the company has designed a targeted approach to activate CD40 selectively in the tumor microenvironment. This approach is based on a multi-specific DARPin® molecule that incorporates a DARPin® directed to fibroblast activation protein (FAP) to localize an agonistic CD40 DARPin® selectively in solid tumors with the goal of increasing efficacy while reducing systemic toxicity. Preclinical data demonstrated that the company’s multi-specific FAP x CD40 DARPin® molecule induced FAP-dependent activation of B cells, dendritic cells and macrophages.

Immuno-oncology: Novel T-cell engager platform presented at PEGS Boston

On April 10, 2019, the company presented the first preclinical data on its novel T cell engager platform based on DARPin® molecules. Initial data suggest that the company’s T cell engaging DARPin® molecule matches antibody-based reference molecules in critical functional dimensions, has excellent biophysical properties and can be formatted with albumin binders for half-life extension.

Oncology: DARPin® drug conjugates (DDCs) highlighted at AACR 2019

The versatility of DARPin® molecules renders them an attractive alternative to antibodies for the development of drug conjugates. Molecular Partners has developed DARPin® drug conjugates (DDCs) in collaboration with ImmunoGen using a model EGFR multi-specific DARPin® molecule. The DDCs displayed antigen-specific activity across a panel of cell lines expressing EGFR with selectivity and potency similar to that observed with antibody-drug conjugates.

Abicipar: MAPLE results underline further progress of abicipar on its way towards market launch expected by Allergan in 2020

On April 2, 2019, Allergan and Molecular Partners announced topline safety results from MAPLE, a 28-week open-label study which enrolled 123 patients and evaluated the safety of abicipar produced via a modified manufacturing process. As a result of the improvements in the manufacturing process, the incidence of intraocular inflammation (IOI) in the MAPLE study was lower than the rate observed in prior Phase 3 studies. Most IOI events were assessed as mild to moderate in severity. The incidence of severe IOI was more than halved to 1.6 percent, with one reported case of iritis and one reported case of uveitis. There were no reported cases of endophthalmitis or retinal vasculitis in this study.

The reduction of the inflammation data shown in MAPLE reinforces the positive efficacy data from previously reported Phase 3 trials. In those CEDAR and SEQUOIA trials, abicipar demonstrated its potential to transform the way physicians manage neovascular AMD with an anti-VEGF therapy. Clinical trial evidence has shown that fixed-interval dosing of anti-VEGF therapies administered either every month or every eight weeks results in better visual outcomes compared to real-world clinical outcomes. Abicipar could be the first fixed 12-week anti-VEGF treatment that improves visual outcomes in a real-world setting for a large number of AMD patients. A fixed-interval 12-week therapy would greatly reduce the treatment burden for patients with nAMD.

Additional data presented at the ARVO Conference in Vancouver on May 02, 2019 highlighted abicipar’s higher cumulative probability of achieving clearance of sub-retinal fluid, an absence of intra-retinal thickening, as well as an absence of all fluids compared to Lucentis®.

Allergan expects to file the abicipar Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the first half of 2019. Allergan plans to present additional data from the MAPLE study at a scientific conference later in 2019.

Balance sheet: Strong cash and equity positions as of March 31, 2019

Molecular Partners’ financial performance for the first quarter 2019 reflects the cash collection of the USD 50 million upfront payment from Amgen for the MP0310 collaboration. Cash and short-term deposits increased by CHF 37.5 million compared to year-end 2018 to CHF 136.5 million as of March 31, 2019.

Also as a consequence of the upfront payment collected from Amgen, the net cash flow from operating activities increased by CHF 29.0 million to CHF 37.5 million for the first quarter 2019 compared to the same period 2018.

As of March 31, 2019, the company employed 123 FTEs (+9% year-over-year), with approximately 85% of employees serving in R&D functions. This continued increase reflects the ongoing build-out of Molecular Partners’ research activities as well as internal clinical development competencies and resources.

“We were able to reinforce our solid cash position with the collected USD 50 million upfront payment from our strategic collaboration with Amgen. This further increases our financial flexibility to capture multiple value-creating inflection points into H2 2020, beyond Allergan’s expected market launch of abicipar and the related expected steady income stream from there on,” said Andreas Emmenegger, Chief Financial Officer of Molecular Partners.

Business outlook and priorities

In 2019, Molecular Partners will continue to advance its DARPin® candidates within its immuno-oncology pipeline and will present further research and preclinical data for additional therapeutic candidates resulting from the company’s immuno-oncology toolbox. For the company’s most advanced IO candidate, MP0310, Molecular Partners and its strategic collaboration partner Amgen expect to enter into a clinical phase 1 monotherapy trial in H2 2019.

In oncology, the company will present additional data from its ongoing phase 2 trial of MP0250 in patients with multiple myeloma (MM) in combination with Velcade® (PI). The company also expects to start the phase 2 trial of MP0250 in combination with Pomalidomide® (IMiD) for the same indication, pending outcomes of the discussion with the FDA. Molecular Partners also expects initial data for MP0274, the proprietary DARPin® candidate for the treatment of HER2-positive cancer, in 2019.

In ophthalmology, following the encouraging improvement of IOI levels as reported in the MAPLE trials, complementing the differentiating phase 3 efficacy data of abicipar in patients with neovascular AMD, Allergan plans to file abicipar with the FDA in H1 2019. Molecular Partners will continue to support Allergan in advancing abicipar through the phase 3 trials and in further optimizing the abicipar formulation. Allergan indicated at its Q1 2019 earnings call its intention to launch the phase 3 study for abicipar in DME in 2020.

Financial outlook 2019

For the full year 2019, at constant exchange rates, the company expects total expenses of CHF 60-70 million, of which around CHF 6 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciations. This reduced guidance reflects the suspension of the enrollment into the NSCLC trial for MP0250 as well as the reduced investment in manufacturing scale-up for phase 3 material trials for MP0250. Capital expenditures in FY 2019 are expected to be approximately CHF 2 million.

This guidance is subject to the progress of the pipeline, mainly driven by the speed of enrollment of patients in clinical trials, manufacturing costs, and data from research and development projects. No guidance can be provided with regard to net cash flow projections. Timelines and potential milestone payments for existing and potentially new partnerships are not disclosed.

Financial Calendar

August 27, 2019 Publication of Half-year Results 2019 (unaudited)
October 31, 2019 Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than five targets, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in preclinical development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid and hematological tumors. MP0274, the second-most advanced DARPin® candidate owned by Molecular Partners, binds to Her2 and inhibits downstream signaling, which leads to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its “I/O toolbox” and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting

Zurich-Schlieren, April 16, 2019. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority.

At today’s Annual General Meeting of Molecular Partners AG, Bill Burns, Göran Ando, Gwen Fyfe, Steven H. Holtzman, William A. Lee, Petri Vainio and Patrick Amstutz were re-elected as members of the Board of Directors for a term of office until the 2020 Annual General Meeting. Bill Burns was re-elected as Chairman of the Board of Directors. The shareholders also elected the three proposed members of the Nomination and Compensation Committee – Bill Burns, Göran Ando and William A. Lee.

KPMG AG Zurich was re-elected as the Group’s statutory auditors for the financial year 2019 and Anwaltskanzlei Keller KLG, Zurich, elected as the independent proxy for a term of office until the 2020 Annual General Meeting.

The Annual General Meeting approved all (binding) motions regarding compensation of the Board of Directors and the Management Board. Further, the shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2018, the appropriation of the 2018 results, as well as the compensation report (in a consultative vote). The Board of Directors and the Management Board were granted discharge for the financial year 2018.

Financial Calendar

  • May 9, 2019 – Interim Management Statement Q1 2019
  • August 27, 2019 – Publication of Half-year Results 2019 (unaudited)
  • October 31, 2019 – Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its ‘I/O toolbox’ and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol

The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation

Previously reported positive Phase 3 results demonstrated the potential for abicipar to be the first anti-VEGF therapy to maintain initial vision gains in all patients on a true fixed 12-week dosing interval

Abicipar BLA submission to the FDA planned for first half of 2019

DUBLIN, IRELAND – April 2, 2019 – Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® therapies, today announced topline safety results from MAPLE, a 28 week open-label study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process. In this single arm study, treatment naïve or prior anti-VEGF treated patients received three monthly 2mg abicipar injections followed by 2mg injections every 8 weeks for up to a total of five injections through week 28.

As a result of the improvements in the manufacturing process, the incidence of intraocular inflammation (IOI) was 8.9 percent in the MAPLE study, which was lower than the rate observed in prior Phase 3 studies. Most IOI events were assessed as mild to moderate in severity. The incidence of severe IOI was 1.6 percent with one reported case of iritis and one reported case of uveitis. There were no reported cases of endophthalmitis or retinal vasculitis in this study.

“It is encouraging to see the lower incidence and type of IOI observed in this open label 28-week study,” said Raj Maturi, MD, Midwest Eye Institute & Associate Professor Ophthalmology, Indiana University School of Medicine. “In the Phase 3 trials previously reported, abicipar demonstrated potential that could transform the way physicians manage nAMD with anti-VEGF therapy. Abicipar could be the first fixed 12- week anti-VEGF treatment that improves visual outcomes in a real world setting for a large number of AMD patients.”

“The results of this open-label study enabled us to assess improvements to the manufacturing process for abicipar. The safety profile demonstrated in MAPLE gives us confidence to proceed and scale up manufacturing,” said David Nicholson, Chief Research and Development Officer, Allergan. “We plan to submit the abicipar BLA and continue to pursue manufacturing process improvements as we develop larger scale studies in additional disease states, such as Diabetic Macular Edema.”

“Clinical trial evidence has shown that fixed-interval dosing of anti-VEGF therapies administered either every month or every 8 weeks results in better visual outcomes compared to real world clinical outcomes. Abicipar could potentially be the first anti-VEGF therapy that is administered every 12 weeks with demonstrated maintenance of visual acuity for a large number of patients with nAMD. A fixed-interval Q12-week therapy would greatly reduce the treatment burden for these patients,” said Peter Kaiser, MD, Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Cole Eye Institute.

“Abicipar is our first DARPin® candidate on track for BLA submission with the aim to become the first fixed 12-week anti VEGF drug in all patients with nAMD,” commented Michael T. Stumpp, COO of Molecular Partners. He added: “The safety data from the MAPLE trial are an important step in the further improvement of the manufacturing process of abicipar.”

Allergan expects to file the abicipar Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the first half of 2019. Additional data from the MAPLE study will be presented at a scientific conference later in 2019.

About ABICIPAR CEDAR and SEQUOIA PHASE 3 TRIALS

Allergan plc and Molecular Partners previously announced results from two positive Phase 3 clinical trials, CEDAR and SEQUOIA for abicipar, a novel DARPin® therapy for the treatment of nAMD, demonstrating that both the 8-week and 12-week fixed-interval treatment regimens met the pre-specified primary endpoint of non-inferiority to ranibizumab. The primary endpoint measured the proportion of treated patients with stable vision at week 52. In both studies abicipar demonstrated similar efficacy after 6 or 8 injections, compared to 13 ranibizumab injections in the first year of this study.

In the CEDAR study, overall treatment-emergent adverse events were similar among the three treatment arms and reported in 73.7 percent, 81.1 percent and 73.2 percent of patients receiving abicipar Q8, abicipar Q12 and ranibizumab Q4, respectively. Incidence of intraocular inflammation events was similar among the two abicipar treatment groups but higher than the ranibizumab group and reported at 15.1 percent and 15.4 percent of patients in the abicipar Q8 and Q12 arms compared to 0 percent in the ranibizumab Q4.

In the SEQUOIA study, overall treatment-emergent adverse events were similar among the three treatment arms and reported in 78.3 percent, 78.0 percent and 74.0 percent of patients receiving abicipar Q8, abicipar Q12 and ranibizumab Q4, respectively. Incidence of intraocular inflammation events was similar among the two abicipar treatment groups but higher than the ranibizumab group and reported at 15.7 percent and 15.3 percent of patients in the abicipar Q8 and Q12 arms compared to 0.6 percent in the ranibizumab Q4 arm.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

Contacts Allergan

Investors:
Manisha Narasimhan, Ph.D., +1 (862) 261-7162

Media:
Amy Rose, +1 (862) 289-3072
Fran DeSena, +1 (862) 261-8820

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotechnology company that is developing a new class of therapies known as DARPin® therapies. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

Contacts Molecular Partners AG

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 (0) 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617-903-8783

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners to present pre-clinical data on its FAP x CD40 multi-DARPin® molecule and on DARPin® drug conjugates (DDCs) at the AACR 2019

Zurich-Schlieren, March 29, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the company will present new pre-clinical data highlighting the company’s immuno-oncology and DARPin® directed drug delivery (DDC) platforms at the Annual Meeting 2019 of the American Association of Cancer Research (AACR) in Atlanta.

Using Molecular Partners’ novel and modular immuno-oncology toolbox, the company has designed a targeted approach to activate CD40 selectively in the tumor microenvironment. This approach is based on a multi-specific DARPin® molecule that incorporates a DARPin® directed to fibroblast activation protein (FAP) to localize an agonistic CD40 DARPin selectively in solid tumors with the goal of increase efficacy while reducing systemic toxicity.  Preclinical data demonstrated that the company’s multi-specific FAP x CD40 DARPin® molecule induced FAP-dependent activation of B cells, dendritic cells and macrophages.

The versatility of DARPin® molecules also makes them an attractive alternative to antibodies for the development of drug conjugates. Molecular Partners has developed DARPin® drug conjugates (DDCs) in collaboration with ImmunoGen, Inc., (Nasdaq: IMGN), using a model EGFR multi-specific DARPin® molecule. The DDCs displayed antigen-specific activity across a panel of cell lines expressing EGFR. DARPin® drug conjugates combine the selectivity and potency observed with antibody drug conjugates and the novel modular design of DARPin® molecules to create specifically designed therapeutics.

“We are very pleased with our advancing pipeline of DARPin® based therapeutics which includes both DDCs and immuno-oncology agents.  The data presented at AACR showcase the innovative power of the DARPin® platform in the multi-specific biologics space,” commented Pamela A. Trail, Chief Scientific Officer of Molecular Partners.

The data will be presented at the following AACR 2019 sessions under the respective titles:

CD40: Tuesday, 2 April 2019, 8.00 am, section 25: 3251 / 1 – “Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin® molecule for tumor-localized immune activation” (Rigamonti et al.)

DDC: Sunday, 31 March 2019, 1.00 pm, section 9: 215 / 6 – “Generation of site-specific DARPin® drug conjugates using EGFR as a model system” (Laviolette et al.)

Full details on the Molecular Partners’ sessions at AACR 2019 as well as all presentations can be found on the conference page. Following their presentation at the AACR, the posters will also be available on the corresponding section of the Molecular Partnerswebsite.

Financial Calendar

  • April 16, 2019 – Annual General Meeting
  • May 9, 2019 – Interim Management Statement Q1 2019
  • August 27, 2019 – Publication of Half-year Results 2019 (unaudited)
  • October 31, 2019 – Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its ‘I/O toolbox’ and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners Publishes Invitation to Annual General Meeting 2019

Zurich-Schlieren, March 19, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today published the invitation to the Annual General Meeting 2019.

The Annual General Meeting will be held on Tuesday, April 16, 2019, 2.00 pm CET (doors open at 1.30 pm CET), at the registered office of the company:

Molecular Partners AG, Wagistrasse 14, 5th floor, 8952 Schlieren, Switzerland

Link to the Invitation to the Annual General Meeting 2019 with the corresponding agenda items.

Link zur Einladung zur Generalversammlung 2019 mit den zugehörigen Traktandenpunkten.

Financial Calendar

  • April 16, 2019 – Annual General Meeting
  • May 9, 2019 – Interim Management Statement Q1 2019
  • August 27, 2019 – Publication of Half-year Results 2019 (unaudited)
  • October 31, 2019 – Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its ‘I/O toolbox’ and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018

Zurich-Schlieren, March 15, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today published its audited Financial Results for 2018 and the company’s 2018 Annual Report.

The Audited Financial Results for 2018 and the company’s 2018 Annual Report are available on the investors section of the company’ website.

Financial Calendar

  • March 19, 2019 – Expected Publication of Invitation to Annual General Meeting
  • April 16, 2019 – Annual General Meeting
  • May 9, 2019 – Interim Management Statement Q1 2019
  • August 27, 2019 – Publication of Half-year Results 2019 (unaudited)
  • October 31, 2019 – Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners to present at the Cowen and Company 39th Annual Healthcare Conference

Company to highlight the progress on its clinical DARPin® compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin® molecules targeting peptide MHC complexes supported by Gilead

Zurich-Schlieren, March 11, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that it will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 12:00 – 12:30 PM Eastern Time (5:00 PM CET). The presentation, followed by a Q&A session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners.

Next to highlighting the progress of the clinical DARPin® compounds, the presentation will outline the evolution of the company’s therapeutic design space in oncology research, including the recent strategic partnership with Amgen on MP0310 (FAP x 4-1BB). The presentation will also outline the initiation of a research project to explore DARPin® molecules targeting peptide MHC complexes supported by Gilead. The ability to target peptide MHC complexes with DARPin® molecules has the potential to open the target space significantly, as these targets have been notoriously difficult to be addressed by any antibody-based approaches.

Audio webcast

The presentation will be webcast live. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website www.molecularpartners.com under the Investors section. The replay will be available for 30 days following the presentation.

Financial Calendar

  • March 15, 2019 – Expected Publication of Annual Report 2018
  • April 16, 2019 – Annual General Meeting
  • May 9, 2019 – Interim Management Statement Q1 2019
  • August 27, 2019 – Publication of Half-year Results 2019 (unaudited)
  • October 31, 2019 – Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners reports key financials for FY 2018 and corporate highlights for Q4 2018

Company positioned for growth following positive phase 3 abicipar data and validation of DARPin® platform through Amgen collaboration

Research & Development:

  • MP0310: Molecular Partners and Amgen announced strategic collaboration for clinical development and commercialization of lead IO candidate MP0310 (FAP x 4-1BB), validating the company’s immuno-oncology toolbox and DARPin® platform; first-in-human trial planned for H2 2019
  • MP0250 and MP0274: Additional patient data of ongoing phase 2 trial of MP0250 in combination with Velcade® in MM support data observed in first patient cohort; Complementary phase 2 trial of MP0250 in combination with Pomalyst® (IMiD) in MM in preparation; Recruitment of first patient cohort for phase 1 trial of MP0274 completed
  • Abicipar (Allergan partnership): Phase 3 secondary endpoint data presented in Q4 2018 underline potential to become first fixed 12 week anti-VEGF for wet AMD; Allergan plans to file abicipar with the FDA in H1 2019 and expects results of MAPLE trial in H1 2019

Team:

  • Talent base of 118 full-time employees (+10% year-on-year), reflecting further build-out of oncology expertise

Financial Highlights:

  • Strong financial position with CHF 99.0 million in cash as of December 31, 2018
  • USD 50 million upfront payment from collaboration agreement with Amgen collected in January 2019
  • Net cash used in operating activities of CHF 42.5 million in 2018, reflecting further build-out of R&D and clinical pipeline
  • Operating loss of CHF 37.4 million and net loss of CHF 37.0 million in 2018
  • Company funded into H2 2020, which is beyond Allergan’s expected abicipar launch resulting in expected steady income stream for Molecular Partners

Zurich-Schlieren, Switzerland, February 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for abicipar as well as the initiation of a strategic collaboration with Amgen in the field of immuno-oncology, two key milestones for the company.

“This was an important year for Molecular Partners in our key focus areas of oncology and immuno-oncology, including the presentation of the clinical strategy for MP0250 and the further development of our immuno-oncology portfolio. In addition, our partnership with Amgen in immuno-oncology validates our innovative therapeutic designs and our successful transition into oncology,” said Dr. Patrick Amstutz, Chief Executive Officer of Molecular Partners. “Positive data from the ongoing trials of abicipar in ophthalmology continue to underscore the therapeutic power of the DARPin® platform. We are now preparing our company for the next phase of growth, marked by Allergan’s expected launch of abicipar as early as 2020.”

MP0250: Update on phase 2 trial of MP0250 plus Velcade®/dexamethasone in multiple myeloma at ASH and company’s R&D Day in New York; complementary trial of MP0250 plus Pomalyst®/dexamethasone starts in 2019

MP0250, Molecular Partners’ lead oncology asset, is a multi-DARPin® candidate that targets hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF), targeting two prominent pathways involved in tumor progression. Both pathways contribute to adaptive resistance to several targeted therapies and MP0250 may have the potential to overcome such adaptive resistance mechanisms.

At the ASH conference in December 2018, the company presented an update on its ongoing phase 2 trial evaluating MP0250 in combination with bortezomib (Velcade®) and dexamethasone in patients with multiple myeloma who had failed standard therapies. Early data from eight patients of the expansion part as per cut-off date of January 31, 2019, support the data observed in the first patient cohort.

The company further discussed potential development strategies for MP0250 at its R&D Day in New York in December 2018 and revealed plans to initiate a second phase 2 trial for MP0250 in MM. In this complementary trial patients will be treated with MP0250 in combination with pomalidomide (Pomalyst®) and dexamethasone. These patients will be relapsed or refractory MM patients who have failed at least two lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) with the most recent therapy being IMiD-based. The ongoing phase 2 trial for MP0250 in MM in combination with Velcade® and dexamethasone is updated to recruit patients with a proteasome inhibitor (PI) based regimen as the most recent therapy. Together, these trials will cover the two main backbones of MM therapy and offer patients the potential to extend treatment with their last-used drug. 

MP0250: Patient recruitment for phase 2 trial in Non-Small Cell Lung Cancer (NSCLC) ongoing

Molecular Partners is continuing patient recruitment for its ongoing phase 1b/2 clinical study of MP0250 in combination with osimertinib (Tagrisso®) in patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) who were pre-treated with osimertinib.

A total of seven patients have been recruited so far at the MP0250 dose of 8mg/kg, dosed every three weeks. As several patients are still on treatment, it is premature to present data on efficacy or toxicity at this point in time.

MP0274 in HER2-positive solid tumors: Recruitment of patient cohort in ongoing Phase 1 trial completed and dose escalation continues

MP0274 is a multi-DARPin® product candidate being developed for the treatment of HER2-positive solid tumors. In preclinical trials MP0274 inhibits downstream signaling pathways, and directly kills HER2-addicted tumor cells through the induction of apoptosis. This represents a new and differentiated mode of action as compared to current standard of care antibodies. Recruitment for the first patient cohort has been completed and the dose escalation phase continues.

MP0310: Strategic immuno-oncology collaboration will jointly develop MP0310 in combination with Amgen’s oncology assets

On December 19, 2018, the company announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).

Under the terms of the agreement, Amgen obtains exclusive global development and commercial rights for MP0310. The parties will jointly evaluate MP0310 in combination with Amgen’s oncology pipeline products, including its investigational BiTE®(bispecific T cell engager) molecules. Under the collaboration, Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin® pipeline products in combination with MP0310.

In January 2019, Molecular Partners collected an upfront payment of USD 50 million. The company is further eligible to receive up to USD 497 million in development, regulatory and commercial milestone payments, as well as double-digit, tiered royalties up to the high teens. The parties agreed to share the clinical development costs in defined percentages for the first three indications subject to certain conditions. For all additional clinical trials, Amgen is responsible for all development costs.

Immuno-oncology: Preclinical data on the company’s DARPin® toolbox and on MP0310 highlighted at multiple scientific conferences

In Q4 2018, the company presented preclinical data on MP0310 at multiple scientific conferences. Moreover, Molecular Partners presented data on FAP x CD40, a second multi-specific preclinical DARPin® molecule in immuno-oncology. In 2019, the company plans to further advance DARPin® candidates arising from its immuno-oncology toolbox as well as to test other differentiating therapeutic designs with its DARPin® approaches.

Abicipar: Potential to be the first fixed 12 week anti-VEGF for nAMD

In Q4 2018, Allergan presented phase 3 safety and efficacy data of abicipar from SEQUOIA and CEDAR, two ongoing and identical global phase 3 trials designed to assess the efficacy and safety of abicipar compared with ranibizumab (Lucentis®) in treatment-naive patients with neovascular age-related macular degeneration (nAMD). These data underscore abicipar’s potential to become the first fixed 12-week anti-VEGF therapeutic.

Allergan consequently reiterated its intention to file the abicipar BLA with the Food and Drug Administration (FDA) in H1 2019 and continues to plan the market launch for 2020. Additionally, Allergan expects to share results from the MAPLE study, testing a further optimized formulation of abicipar, in H1 2019.

Financial highlights: Collaboration with Amgen further increased solid financial flexibility

In the financial year 2018, Molecular Partners recognized total revenues of CHF 10.4 million (2017: CHF 20.0 million) and incurred total expenses of CHF 47.8 million (2017: CHF 45.8 million). This led to an operating loss of CHF 37.4 million for 2017 (2017: Operating loss of CHF 25.8 million). The net financial result of CHF 0.4 million recorded in 2018 remained on the same level as in 2017. This resulted in a 2018 net loss of CHF 37.0 million (2017: Net loss of CHF 25.4 million).

The net cash used for operating activities in 2018 was CHF 42.5 million (2017: net cash used of CHF 40.0 million). Including time deposits, the cash and cash equivalents position decreased by CHF 42.1 million vs. year-end 2017 to CHF 99.0 million as of December 31, 2018 (December 31, 2017: CHF 141.1 million). Total shareholders’ equity stood at CHF 91.7 million as of December 31, 2018, a decrease of CHF 25.0 million (December 31, 2017: CHF 116.7 million). The USD 50 million upfront payment from the strategic collaboration with Amgen was collected in January 2019 and further increases the company’s solid cash position with no debt on the balance sheet.

Key figures as of December 31, 2018

Key Financials (unaudited) FY 2018 FY 2017 change
(CHF million, except per share, FTE data)
Total revenues 10.4 20.0 (9.6)
R&D expenses (38.2) (37.4) (0.8)
G&A expenses (9.6) (8.4) (1.2)
Operating result (37.4) (25.8) (11.6)
Net financial result 0.4 0.4 0.0
Net result (37.0) (25.4) (11.6)
Basic net result per share (in CHF) (1.75) (1.22) (0.53)
Net cash from (used in) operating activities (42.5) (40.0) (2.5)
Cash balance (incl. time deposits) as of Dec. 31 99.0 141.1 (42.1)
Total shareholders’ equity as of Dec. 31 91.7 116.7 (25.0)
Number of total FTE as of Dec. 31 117.7 107.8 9.9
– thereof in R&D 104.4 96.5 7.9
– thereof in G&A 13.3 11.3 2.0

As a result of the adoption of IFRS 15, deferred revenues as of December 31, 2017 of CHF 18.4 million were partly reclassified to equity (CHF 9.0 million) in the IFRS financial statements to reflect the accumulated past effect of the adoption as of January 1, 2018. The remaining portion of CHF 9.4 million was recognized as revenues due to the option exercise in relation to the Discovery Alliance Agreement with Allergan in 2018. The remaining revenue in 2018 was generated from the Amgen agreement in December 2018.

As of December 31, 2018, the company employed 118 FTE, up 10% compared to year-end 2017. About 90% of the employees are employed in R&D-related functions.

“In the course of 2018, Molecular Partners’ financial position continued to develop in line with our expectations. We were able to reinforce our solid cash position with the USD 50 million upfront payment from the strategic collaboration with Amgen. This further increases our financial flexibility to capture multiple value-creating inflection points into H2 2020, beyond Allergan’s expected market launch of abicipar and the related expected steady income stream from there on,” said Andreas Emmenegger, Chief Financial Officer of Molecular Partners. “As we are setting up our organization for growth, we plan to substantially increase investments, mainly into our clinical program as well as into the expansion of our workforce.”

Business outlook and priorities

In 2019, Molecular Partners will present additional data from its ongoing phase 2 trials of MP0250 in patients with multiple myeloma (MM). The company also expects to present initial data of its phase 1b/2 study of MP0250 in EGFR-mut NSCLC in 2019. The company also expects data in 2019 for MP0274, the proprietary, single-pathway DARPin® drug candidate for the treatment of HER2-positive cancer.

The company will continue to advance its DARPin® candidates within its immuno-oncology pipeline, and will present further research and preclinical data for additional therapeutic candidates resulting from the company’s immuno-oncology toolbox. For the company’s most advanced IO candidate, MP0310, Molecular Partners and its strategic collaboration partner Amgen expect to enter into a clinical phase 1 monotherapy trial in H2 2019.

In ophthalmology, following the differentiating phase 3 efficacy data of abicipar in patients with wet AMD, Allergan plans to file abicipar with the FDA in H1 2019. Allergan also continues to expect results from the MAPLE study, using the further optimized formulation of abicipar, in H1 2019. Molecular Partners will continue to support Allergan in advancing abicipar through the phase 3 trials and in further optimizing the abicipar formulation. Allergan indicated its intention to launch the phase 3 study for abicipar in DME in H2 2019. Finally, the company continues to support Allergan in advancing the three preclinical ophthalmology assets optioned-in from the existing research collaboration.

Financial outlook 2019

For the full year 2019, at constant exchange rates, the company expects total expenses of CHF 70-80 million, of which around CHF 7 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciations. The increase versus the previous year is mainly driven by the progress of the company’s pipeline, additional clinical trials for MP0250, the start of manufacturing of phase 3 material for MP0250 as well as the budgeted growth of the company’s workforce. Capital expenditures in FY 2019 are expected to be approximately CHF 3 million.

This guidance is subject to the progress of the pipeline, mainly driven by manufacturing costs, the speed of enrollment of patients in clinical trials and data from research and development projects. No guidance can be provided with regard to net cash flow projections. Timelines and potential milestone payments for existing and potentially new partnerships are not disclosed.

Investor documentation of FY 2018 results

This FY 2018 press release as well as the FY 2018 results presentation are available on the investors section of the company’s website.

FY 2018 results presentation, conference call and audio webcast

Molecular Partners will hold the FY 2018 results presentation in its headquarters in Zurich-Schlieren on February 07, 2019, 2:00pm CET (1:00pm GMT, 8:00am EST). For those who are unable to participate in the live event, the company provides conference call and audio webcast capabilities.

In order to register for the FY 2018 conference call, please dial the following numbers approximately 10 minutes before the start of the presentation:

Switzerland / Europe: +41 (0) 58 310 5000

UK: +44 (0) 203 059 5862

USA: +1 (1) 631 570 5613

Participants will have the opportunity to ask questions after the presentation.

The FY 2018 audio webcast will be accessible, both live and as a replay, on the investors section of the company’s website www.molecularpartners.com, along with the accompanying presentation slides.

Financial Calendar

March 15, 2019 Expected Publication of Annual Report 2018
April 16, 2019 Annual General Meeting
May 9, 2019 Interim Management Statement Q1 2019
August 27, 2019 Publication of Half-year Results 2019 (unaudited)
October 31, 2019 Interim Management Statement Q3 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners to Present at the 37th Annual J.P. Morgan Healthcare Conference

Company to highlight recent progress on clinical DARPin® compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310

Zurich-Schlieren, January 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:00 AM Pacific Standard Time (11:00 AM Eastern Time; 5:00 PM CET). The presentation, followed by a Q&A session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners.

Beyond highlighting the progress of the clinical DARPin® compounds and the evolution of the company’s therapeutic design space in oncology research, the presentation will outline the collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB) which the company and Amgen (NASDAQ:AMGN) announced on December 19, 2018. MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).

Audio webcast

The presentation will be webcast live. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website www.molecularpartners.com under the Investors section. The replay will be available for 30 days following the presentation.

Financial Calendar

  • February 7, 2019 – Publication of Full-year Results 2018 (unaudited)
  • March 15, 2019 – Expected Publication of Annual Report 2018
  • April 16, 2019 – Annual General Meeting
  • May 9, 2019 – Interim Management Statement Q1 2019

http://investors.molecularpartners.com/financial-calendar-and-events/

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics.
The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin®therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Thomas Schneckenburger, IR Europe
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.